Pro-life leaders criticized the U.S. Senate’s Feb. 15 confirmation of Dr. Robert Califf as President Joe Biden’s commissioner of the Food and Drug Administration, taking issue with Califf’s role in the agency expanding the availability of the drug protocol used for chemical abortions.
By no longer requiring the abortion drug mifepristone to be picked up in person, the U.S. Food and Drug Administration is “merely succumbing to the abortion industry’s pressure to loosen safety standards,” instead of protecting the lives and health of mothers and children as it should do, he said.
The decision by the acting commissioner of the U.S. Food and Drug Administration to suspend enforcement of the agency’s in-person prescribing requirement for the abortion drug endangers women’s health and possibly their lives, pro-life leaders said.
U.S. Supreme Court is temporarily allowing drugs used to medically induce abortions to be mailed or delivered without requiring the recipient to make a doctor’s visit during the coronavirus pandemic.
WASHINGTON (CNS) — Pro-life advocates expressed dismay with new Food and Drug Administration guidelines that effectively expand how pregnant women can use RU-486, a drug that […]
